Atomwise and Bridge Biotherapeutics Sign $1B Deal to Unlock Blockbuster Potential in Inflammation

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Atomwise Inc.
  • Source:
    Business Wire (English). 03/09/2020.
  • Additional Information
    • Abstract:
      Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics, a clinical stage biotech company, announced today a research collaboration to launch up to 13 small molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery. Under the agreement, Atomwise will evaluate and initiate programs for Pellino E3 ubiquitin ligases and other targets nominated by Bridge. [ABSTRACT FROM PUBLISHER]